# Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market
Canonical URL: https://biopharmsignal.com/news/AZYO/elutia-reports-first-quarter-2026-results-and-highlights-nxt-41x-progress-toward-1-5-billion-u-s-plastic-and-reconstructive-surgery-market
Ticker: AZYO
Company: Aziyo Biologics
Source: Aziyo Biologics
Published: 2026-05-14 20:06 EST
Original Source URL: https://investors.elutia.com
## Summary

NXT-41 review advancing collaboratively with FDA, informing NXT-41x submission preparations Brought a new automated manufacturing process online, supporting a gross margin target of more than 80% at scale Chief Commercial Officer Pete Ligotti's initial surgeon engagement confirming significant

## Article Body
NXT-41 review advancing collaboratively with FDA, informing NXT-41x submission preparations Brought a new automated manufacturing process online, supporting a gross margin target of more than 80% at scale Chief Commercial Officer Pete Ligotti's initial surgeon engagement confirming significant
## Recent Company News
- 2026-05-14 20:06 EST — [Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market](https://biopharmsignal.com/news/AZYO/elutia-reports-first-quarter-2026-results-and-highlights-nxt-41x-progress-toward-1-5-billion-u-s-plastic-and-reconstructive-surgery-market) — Source: Aziyo Biologics
- 2026-05-14 20:01 EST — [Elutia to Present at the 16th Annual LD Micro Invitational on May 18th](https://biopharmsignal.com/news/AZYO/elutia-to-present-at-the-16th-annual-ld-micro-invitational-on-may-18th) — Source: Aziyo Biologics
- 2026-04-30 20:05 EST — [Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026](https://biopharmsignal.com/news/AZYO/elutia-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026) — Source: Aziyo Biologics
- 2026-03-17 12:00 EST — [Elutia to Present at Sidoti’s Small-Cap Virtual Investor Conference March 18-19](https://biopharmsignal.com/news/AZYO/elutia-to-present-at-sidoti-s-small-cap-virtual-investor-conference-march-18-19) — Source: Aziyo Biologics
- 2026-03-13 12:00 EST — [Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AZYO/elutia-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4) — Source: Aziyo Biologics
## Related News
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)